Loading company
Paysign, Inc.
PAYS · Nasdaq · ·
Next earnings: November 11, 2026
$12.87+1.2%Sep 29 close
- 1M
- -0.2%
- 6M
- +123.4%
- 1Y
- +104.6%
- 5Y
- +345.3%
PAYS · Nasdaq · ·
Next earnings: November 11, 2026
$12.87+1.2%Sep 29 close
Paysign, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $28.3M | $19.1M | +48.08% |
| Profit | $6.8M | $1.4M | +386.87% |
| Profit per share | $0.11 | $0.02 | +450.00% |
| Free Cash Flow | $1.2M | $3.6M | -66.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Paysign delivered a strong second quarter, achieving record revenue, net income, and adjusted EBITDA while continuing to expand margins,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence, enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers, pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they serve.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Paysign, Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Paysign, Inc. has no earnings call transcript available.